Skip to main content
ORTHOCELL LIMITED logo

ORTHOCELL LIMITED — Investor Relations & Filings

Ticker · OCC ISIN · AU000000OCC6 ASX Manufacturing
Open in API
Filings indexed 780 across all filing types
Latest filing 2025-02-27 Share Issue/Capital Cha…
Country AU Australia
Listing ASX OCC

About ORTHOCELL LIMITED

https://orthocell.com/

Orthocell Limited is a regenerative medicine company focused on the development and commercialization of innovative technologies for the repair and regeneration of human soft tissue. The company’s core product portfolio includes the CelGro platform, a naturally derived collagen medical device designed to facilitate tissue repair and reconstruction in applications such as dental bone and soft tissue regeneration, nerve repair, and tendon repair. Orthocell also specializes in advanced cellular therapies, notably Ortho-ATI (Autologous Tenocyte Implantation) for treating chronic tendon injuries and Ortho-ACI (Autologous Chondrocyte Implantation) for cartilage repair. These therapies utilize a patient's own cells to restore function and structure to damaged tissues. The company aims to provide restorative solutions that improve clinical outcomes and offer alternatives to traditional surgical interventions.

Recent filings

Filing Released Lang Actions
Application for quotation of securities - OCC 8 pages 21.0KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 2A - Application for quotation of securities' and is an announcement by Orthocell Limited regarding the application for quotation of securities on the ASX. It details the issuance and conversion of options/performance rights into ordinary fully paid shares, the number of securities to be quoted, and related information about the securities and issued capital. This is a formal announcement related to the quotation of new securities following conversion of options, which fits the category of Share Issue/Capital Change announcements. It is not a full financial report, earnings release, or management report, but a regulatory announcement about capital changes. Therefore, the appropriate classification is Share Issue/Capital Change (SHA). The document length (7333 characters) and content confirm it is a full announcement, not just a brief notice or report publication announcement.
2025-02-27 English
Orthocell Webinar Presentation 24 pages 2.4MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation titled 'Orthocell Webinar Presentation - Accelerating Global Expansion' dated 26 February 2025. It includes extensive information about the company's products, market expansion, financial highlights such as revenue growth, balance sheet strength, and corporate snapshot. The content is structured as a presentation with slides, images, and detailed business and product information aimed at investors and stakeholders. There is no indication that this is a full annual or quarterly report, audit report, or earnings release. It is not a transcript of a call but rather a prepared presentation for a webinar event. The document is too long and detailed to be a simple announcement or regulatory filing. Therefore, the best fitting category is Investor Presentation (IP).
2025-02-25 English
Orthocell Webinar 2 pages 182.0KB
Investor Presentation Classification · 85% confidence The document is an announcement inviting investors to a webinar hosted by Orthocell Limited to provide an update on the company's global commercial expansion and recent regulatory submissions. It includes details about the webinar timing, registration, and contact information. There are no financial statements, detailed financial analysis, or comprehensive report content. The document is short (4653 characters) and serves as an invitation and update rather than a full report or transcript. It does not contain earnings data, management discussion, or regulatory filings beyond the announcement of the webinar event. Therefore, it fits best as an Investor Presentation (IP) announcement or invitation rather than a full Investor Presentation document. However, since it is primarily an invitation to a webinar with a presentation, the closest classification is Investor Presentation (IP).
2025-02-24 English
Appendix 4D & Half-Year Financial Report 24 pages 4.4MB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'ASX Half-Year Report for 6 months to 31 December 2024' and references the 'Interim Report of Orthocell Limited for the half-year ended 31 December 2024.' It contains detailed financial data including revenues, losses, net tangible assets, and a comprehensive directors' report with operational highlights, corporate directory, auditor's review report, and consolidated financial statements. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement. The content and structure align with a comprehensive interim or quarterly financial report rather than a full annual report or other filing types. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2025-02-23 English
Remplir FDA Application submitted for US$84M Thai Market 3 pages 198.0KB
Capital/Financing Update Classification · 95% confidence The document is a press release announcing Orthocell's submission of a regulatory application to the Thai FDA to commence sales of its product Remplir in the Thai market. It discusses market expansion plans, regulatory approval timelines, and financial position but does not contain any financial statements, detailed financial performance data, or comprehensive report content. The document is primarily an update on regulatory and market expansion activities, typical of a Capital/Financing Update or general corporate announcement. It is not an Annual Report, Interim Report, Earnings Release, or any detailed financial or governance report. Given the content focuses on regulatory application submission and market expansion, the most appropriate classification is Capital/Financing Update (CAP). The document length (8693 characters) and content support this classification with high confidence.
2025-02-20 English
Application for quotation of securities - OCC 10 pages 26.7KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 2A - Application for quotation of securities' and contains detailed information about securities issued, options exercised, and the application for quotation of these securities on the ASX. It includes specifics such as the number of securities, issue dates, exercise prices, and whether the securities are to be quoted. This type of document is a formal application to list or quote new securities on a stock exchange, which aligns with announcements related to share issues or capital changes. It is not a financial report, earnings release, or management discussion, nor is it a regulatory filing or announcement of voting results. Therefore, the document fits best under the category of Share Issue/Capital Change (SHA). The document length is substantial and contains detailed data, confirming it is not merely an announcement of a report but the actual application for quotation of securities.
2025-02-17 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.